ADVERTISEMENT

Prescription To OTC Switch

In Latest US FDA Drug Center Change, Lead In OTC Monograph, Switch Program Overhauls Out

FDA says Teresa Michele, in CDER nonprescription drugs program leadership roles since 2013, was being moved to another position in the agency.

US OTC Switches: FDA Needs Comments To Guide Public Meeting, Congress Wants Progress Report

Agency intends to use information from comments to guide its planning for a public meeting during 2026, according to a Federal Register notice. A GAO report is due in a year to Congress profiling FDA’s progress on making more drugs available nonprescription through OTC switch applications.

‘Barriers May Limit’ Epinephrine Access: FDA Workshop To Discuss OTC Anaphylaxis Indication

Approval of numerous Rx formulations hasn’t translated to wider availability when a remedy is needed for anaphylaxis emergency, say FDA and the Margolis Institute in announcing workshop on reducing anaphylaxis-related morbidity and mortality.

Stopgap Spending Bill Provides Platform To Plug Gaps In FDA’s OTC Monograph, Switch Pathways

OMUFA reauthorization and directions for FDA to provide reports on monograph program and guidance on improving chances for OTC switch applications included in recent stopgap spending bill to end federal government shutdown.

OMUFA Reauthorization: US FDA Would Identify Rx-OTC Switch Candidates, Work With Sponsors

Senate “SMART OTC” Act would require the FDA to identify product categories that could be eligible for an Rx-to-OTC switch and create a framework to work with sponsors.

Greener Propellant Coming For Primatene Mist Before Competition Reaches Market

Amphastar confident Primate Mist asthma spray will lose little market share to eventual generic competitors because it’s developing a propellant with a lower ozone-depleting impact. Also looks for US OTC market revenues from proposed naloxone nasal spray.

Survey Suggests Target Market To Drive Opill Sales

Results of survey of 986 oral contraceptive users 15 to 45 years old published online in JAMA Network Open show OTC access drove a 31.8 percentage-point increase in women shifting from no contraceptive method to an effective method.

Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline

Amphastar plans three- to five-year expansion to quadruple production capacity for its US manufacturing operations at its Rancho Cucamonga, CA, headquarters. Primatene Mist Q2 sales reached $22.88m from $22.86m a year ago.

Repeat Buyers Passing 50% Key For Opill Sales Leading Perrigo’s Women’s Health Growth

“We continue to grow the brand. It was slower than initially anticipated or forecasted in basis, but I'm pleased with how it's developing,” says CEO Patrick Lockwood-Taylor of Opill performance.

Kennedy Appears Ill-Informed On Major Pharma Priorities, Creating Unique Lobbying Dynamics

Health and Human Services secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.

Allergy Ingredient Itch Warning, ACNU Final Rule Scratch Extent Of FDA Authority For Label Changes

Effective date for ACNU OTC switch final rule and finding of severe itching from long-term use of common allergy ingredients are bookends for limits of FDA’s authority for product label changes.

Trump Order To Improve Making More Drugs Available OTC Puts Wind Behind Petros’ ACNU Sails

Petros will incorporate into its platform an analytics firm’s automated document capture and authentication system leveraging its global ID library to verify identity and eligibility of consumers accessing the self-selection process for an ACNU switch.